A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma

Gordon Cook, Sonja Zweegman, María-Victoria Mateos, Florence Suzan, Philippe Moreau

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Multiple classes of agent with distinct mechanisms of action are now available for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM), including immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies. Additionally, several different drugs may be available within each agent class, each with their own specific efficacy and safety profile. This expansion of the treatment landscape has dramatically improved outcomes for patients. However, as the treatment options for RRMM become more complex, choosing the class of agent or combination of agents to use in the relapsed setting becomes increasingly challenging. Furthermore, treatment options for specific patient populations such as the elderly, those with high-risk cytogenetic abnormalities and those with refractory disease are yet to be defined in the current treatment landscape. When choosing an appropriate treatment approach, physicians must consider multiple criteria including both patient-related and disease-related factors. The aim should be to provide patient-specific treatment in order to gain a clinical benefit while minimizing toxicity. This review provides an overview of the mechanism of action and efficacy and safety profiles of each class of agent and of treatment regimens that combine different classes of agent, with a special focus on treating specific patient populations.
Original languageEnglish
Pages (from-to)74-89
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume121
DOIs
Publication statusPublished - 2018

Cite this

Cook, Gordon ; Zweegman, Sonja ; Mateos, María-Victoria ; Suzan, Florence ; Moreau, Philippe. / A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. In: Critical Reviews in Oncology/Hematology. 2018 ; Vol. 121. pp. 74-89.
@article{9131d6b50e9a48d08d8e1254f334db0c,
title = "A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma",
abstract = "Multiple classes of agent with distinct mechanisms of action are now available for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM), including immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies. Additionally, several different drugs may be available within each agent class, each with their own specific efficacy and safety profile. This expansion of the treatment landscape has dramatically improved outcomes for patients. However, as the treatment options for RRMM become more complex, choosing the class of agent or combination of agents to use in the relapsed setting becomes increasingly challenging. Furthermore, treatment options for specific patient populations such as the elderly, those with high-risk cytogenetic abnormalities and those with refractory disease are yet to be defined in the current treatment landscape. When choosing an appropriate treatment approach, physicians must consider multiple criteria including both patient-related and disease-related factors. The aim should be to provide patient-specific treatment in order to gain a clinical benefit while minimizing toxicity. This review provides an overview of the mechanism of action and efficacy and safety profiles of each class of agent and of treatment regimens that combine different classes of agent, with a special focus on treating specific patient populations.",
keywords = "Cytogenetics, Elderly, Multiple myeloma, Refractory, Relapsed",
author = "Gordon Cook and Sonja Zweegman and Mar{\'i}a-Victoria Mateos and Florence Suzan and Philippe Moreau",
year = "2018",
doi = "10.1016/j.critrevonc.2017.11.016",
language = "English",
volume = "121",
pages = "74--89",
journal = "Critical Reviews in Oncology / Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. / Cook, Gordon; Zweegman, Sonja; Mateos, María-Victoria; Suzan, Florence; Moreau, Philippe.

In: Critical Reviews in Oncology/Hematology, Vol. 121, 2018, p. 74-89.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma

AU - Cook, Gordon

AU - Zweegman, Sonja

AU - Mateos, María-Victoria

AU - Suzan, Florence

AU - Moreau, Philippe

PY - 2018

Y1 - 2018

N2 - Multiple classes of agent with distinct mechanisms of action are now available for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM), including immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies. Additionally, several different drugs may be available within each agent class, each with their own specific efficacy and safety profile. This expansion of the treatment landscape has dramatically improved outcomes for patients. However, as the treatment options for RRMM become more complex, choosing the class of agent or combination of agents to use in the relapsed setting becomes increasingly challenging. Furthermore, treatment options for specific patient populations such as the elderly, those with high-risk cytogenetic abnormalities and those with refractory disease are yet to be defined in the current treatment landscape. When choosing an appropriate treatment approach, physicians must consider multiple criteria including both patient-related and disease-related factors. The aim should be to provide patient-specific treatment in order to gain a clinical benefit while minimizing toxicity. This review provides an overview of the mechanism of action and efficacy and safety profiles of each class of agent and of treatment regimens that combine different classes of agent, with a special focus on treating specific patient populations.

AB - Multiple classes of agent with distinct mechanisms of action are now available for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM), including immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies. Additionally, several different drugs may be available within each agent class, each with their own specific efficacy and safety profile. This expansion of the treatment landscape has dramatically improved outcomes for patients. However, as the treatment options for RRMM become more complex, choosing the class of agent or combination of agents to use in the relapsed setting becomes increasingly challenging. Furthermore, treatment options for specific patient populations such as the elderly, those with high-risk cytogenetic abnormalities and those with refractory disease are yet to be defined in the current treatment landscape. When choosing an appropriate treatment approach, physicians must consider multiple criteria including both patient-related and disease-related factors. The aim should be to provide patient-specific treatment in order to gain a clinical benefit while minimizing toxicity. This review provides an overview of the mechanism of action and efficacy and safety profiles of each class of agent and of treatment regimens that combine different classes of agent, with a special focus on treating specific patient populations.

KW - Cytogenetics

KW - Elderly

KW - Multiple myeloma

KW - Refractory

KW - Relapsed

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85040773192&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29279102

U2 - 10.1016/j.critrevonc.2017.11.016

DO - 10.1016/j.critrevonc.2017.11.016

M3 - Review article

VL - 121

SP - 74

EP - 89

JO - Critical Reviews in Oncology / Hematology

JF - Critical Reviews in Oncology / Hematology

SN - 1040-8428

ER -